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To the Editor:  
 Airway hyperresponsiveness (AHR) is associated with an increased mortality risk among men 
[1] and COPD patients [2]. However, this association is largely based on cross-sectional studies using 
a single measurement of AHR to predict mortality; inherently ignoring the longitudinal variability of 
AHR. AHR is variable regardless of disease or medication status, and is linked with changes in 
smoking habits, seasonal variations and exposure to pollutants [3–5]. Considering this, it remains 
unclear how changes in AHR affect mortality, specifically from causes such as COPD, cardiovascular 
disease (CVD) and cancer. 
We used data from the Vlagtwedde-Vlaardingen study (1965 to 1990) [6], a general 
population-based cohort of two communities in the Netherlands followed-up every three years. At 
all visits, AHR was measured with histamine biphosphate administered in increasing doses of 1, 4, 8, 
16 and 32 mg/ml for 30 seconds followed by lung function measurements. The provocation 
concentration (PC10) which caused a steady reduction in inspiratory vital capacity (IVC) or forced 
expiratory volume in one second (FEV1) of more than 10% compared to baseline was then 
considered as the threshold value. Data on weight, height, eosinophil count, smoking habits and 
respiratory symptoms were also collected at each follow-up period. Vital status of all participants 
including specific causes of death was updated on December 31st, 2016 at Statistics Netherlands (The 
Hague, the Netherlands). The causes of death were coded according to the International 
Classification of Diseases (ICD) (versions 7-10).  
We classified AHR based on histamine threshold, with ≤ 8 mg/ml indicating positive AHR 
(responders) and > 8 mg/ml indicating negative AHR (non-responders) [7]. We then included 
subjects who had a minimum of two AHR measurements and categorized changes in AHR from 
baseline (first available measurement) to the last available measurement for each subject as: never 
AHR (if subjects were non-hyperresponsive at baseline and during follow-up), persistent AHR (if 
subjects were hyperresponsive at baseline and during follow-up), remitting AHR (if subjects were 
hyperresponsive at baseline but became non-hyperresponsive during follow-up), developing AHR (if 
subjects were non-hyperresponsive at baseline but became hyperresponsive during follow-up), and 
variable AHR (if subjects did not have a specific trend in AHR, constituting all remaining subjects). 
We calculated subject-specific annual change estimates for continuous variables (BMI, FEV1, 
FEV1/IVC and eosinophil count) by taking the difference between the last and first available 
measurements and standardizing this based on the number of years of follow-up. Changes in 
smoking and dyspnea were used as previously defined [8,9]. Asthma attacks were self-reported 
attacks of shortness of breath with wheezing in any of the visits. 
 The association between changes in AHR and all-cause and cause-specific mortality was 
estimated with Cox proportional-hazards model. The time to event was defined from the last 
available AHR measurement until the date of death or censoring on December 31, 2016. We 
adjusted for lung function by including both baseline FEV1 and the yearly change estimate of FEV1 in 
the model. We also adjusted for other fixed (gender, place of residence, baseline age) and changing 
covariates (BMI, eosinophil count, smoking status, dyspnea and asthma attacks). For cause-specific 
mortality, subjects who died from causes other than the cause of interest were censored at the age 
of death and a competing risk analysis was performed [10]. Subjects who died due to external causes 
of death such as accidents and suicides were excluded from the analysis (n=18).  
In total, 1,464 subjects had at least two AHR measurements. Among these, 702 (47.9%) had 
died by the end of December 31st, 2016 and only 9 (0.6%) were lost to follow-up (Table 1). Among 
those who died, 28 (3.9%) died of COPD, 235 (32.6%) died of CVD, and 255 (35.4%) died due to 
cancer. Deceased subjects had a higher prevalence of AHR, were more often smokers and had lower 
lung function levels at baseline. Subjects who died of COPD had more AHR at baseline (35.7%) than 
those who died of CVD (13.6%) or cancer (10.2%). 
In the adjusted model, none of the four AHR-change categories, compared to never AHR, 
showed a statistically significant association with all-cause mortality. However, the adjusted cause-
specific survival analysis showed a statistically significant association between changes in AHR and 
COPD mortality. Subjects with persistent AHR or variable AHR had a higher risk of dying of COPD 
compared to those who were never hyperresponsive. Specifically, throughout the observation 
period, subjects with persistent AHR were six times more likely to die of COPD (HR: 6.07, 95% CI: 
1.23-29.92) and those with variable AHR were four times more likely to die of COPD (HR: 4.56, 95% 
CI: 1.2-17.24), both compared to those who never had AHR (Table 1). We did not observe a 
significant association between changes in AHR and CVD or cancer mortality.  
 Cockcroft and Davis [11] classified components of AHR as persistent and transient, reflecting 
airway remodelling and airway inflammation respectively. In our study, subjects with persistent AHR 
likely had irreversible airway remodelling. Repetitive stimuli and a constant activation of the repair 
process are mechanisms behind airway remodelling in COPD leading to airway wall thickening, 
decrease in airway lumen size and reduced airflow [12,13]. These mechanisms can accelerate the 
progress of COPD and lead to premature death. Individuals with variable AHR likely present the 
transient component of AHR characterized by airway inflammation [11]. This independence of 
airway restructuring and airway inflammation in COPD [14] suggests potentially distinct 
pathophysiologic mechanisms behind individuals with persistent AHR and variable AHR.  
Clinical management of airway inflammation may possibly ‘normalize’ AHR and lower long-
term mortality risk from COPD but future studies should be performed to investigate this. In our 
study, subjects with remitting AHR did not have a higher risk of COPD mortality compared to the 
never AHR. This suggests that ‘losing’ AHR over time can have a favourable outcome on the risk of 
COPD death, and possibly indicates the gradual attenuation of airway inflammation in some 
individuals [15]. This improvement of AHR can also be related to lifestyle changes including smoking 
cessation and use of medications to manage asthmatic symptoms. Compared to those who died of 
CVD or cancer, subjects who died from COPD had a higher prevalence of asthmatic symptoms 
(wheezing and asthma attack) at baseline.  
A major strength of our study is the extensive follow-up with minimal attrition and the use of 
objective and standardized measurements. People with low lung function levels (FEV1 < 1.5 litres) 
were excluded from AHR measurements. This is important to note since reduced FEV1 is related to 
mortality and AHR, indicating that the results are best generalizable to those with good lung health. 
Although histamine provocation is no longer commonly used due to its adverse effects, it is very 
similar to a methacholine bronchoprovocation test [16]. A PC10 ≤ 8 mg/ml in the 30 seconds protocol 
used in our study is comparable to a PC20 ≤ 4 mg/ml in the 2 minutes protocol, which is the 
recommended cutpoint for positive AHR [17]. We were not able to control for other possible 
confounders such as medication status and use of inhaled corticosteroids (which are shown to 
influence both AHR and COPD mortality), clinical data on lung phenotypes, airway calibre, 
occupational exposure, and ambient air pollution. Finally, the use of administrative data for outcome 
assessment might have introduced some misclassification bias on the causes of death.  
With a longitudinal cohort accruing 51 years of follow-up, repeated AHR measurements and control 
for previously suggested confounders such as lung function and smoking [18], we show that AHR 
that is present at all occasions (persistent) or some occasions but not always (variable) is associated 
with a higher risk of COPD mortality. Early targeting of individuals who display AHR on multiple 
occasions or those with varying AHR measurements could be an important step in reducing COPD 
related deaths.  
 
 
Table 1: Characteristics of the participants classified by changes in AHR  










Male, n (%) 479 (56.4) 25 (61.0) 23 (56.1) 215 (60.2) 104 (59.4) 
Baseline age, mean (SD) 35.5 (10.9) 43.9 (10.1) 42.4 (12.1) 38.8 (10.7) 37.7 (10.7) 
Baseline BMI, mean (SD) 24.9 (3.5) 26.4 (4.1) 26.3 (3.9) 25.6 (3.3) 25.6 (2.7) 
Baseline FEV1 (L), mean (SD) 3.38 (0.75) 2.52 (0.67) 2.67 (0.80) 3.13 (0.66) 3.08 (0.76) 
Baseline FEV1/IVC (%), mean (SD) 79.94 (6.73) 67.57 (11.61) 72.29 (6.57) 76.32 (7.63) 75.31 (8.92) 
Baseline smoking status, n (%) 
   never 
   ex 





















Annual change in BMI, mean (SD) 0.1 (0.2) 0.1 (0.2) 0.1 (0.3) 0.1 (0.2) 0.1 (0.2) 
Annual change in FEV1 (ml/year), mean (SD) -19.3 (39.2) -34.7 (31.0) 5.8 (107.6) -30.7 (28.7) -22.7 (22.9) 
Annual change in FEV1/IVC (%/year), mean (SD) -0.22 (0.70) -0.49 (0.88) 0.08 (1.04) -0.34 (0.58) -0.17 (0.45) 
Change in smoking status, n (%) 
   Persistent never 
   Persistent ex 
   Persistent current 
   Quitter 
   (Re-)Starter 




































Vital status, n (%) 
   Alive 
   Dead 





















Causes of death, n (%) 
   COPD 
   CVD 
   Cancer 


























      
Hazard Ratios, HR (95% CI)
*
 
   All 
   COPD 
   CVD 
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